Cellectis Gets FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis is taking another step to move immunotherapy 'off the shelf.'
Publish date:

Cellectis(CLLS) - Get Report  received an Investigational New Drug, or IND, approval from the U.S. Food and Drug Administration on Monday to conduct phase I clinical trials with UCART123, the biotech's gene-edited product candidate, in patients with acute myeloid leukemia, or AML, and blastic plasmacytoid dendritic cell neoplasm, or BPDCN.

This marks the first allogeneic "off the shelf" gene-edited CAR T-cell product candidate that the FDA has approved for clinical trials.